Feed

Feeds
2 messages
REGN
Regeneron (REGN): EPS Beat, Margin & Regulatory Risks
Aug 1, 2025, 06:33 PM
Quarterly Post-Earnings Summary
Regeneron posted a strong Q2 EPS beat on Dupixent and Libtayo growth, but faces margin pressures, regulatory risks, and declining legacy product sales, making upcoming pipeline and regulatory catalysts critical for investors.
REGN
REGN: Dupixent Offsets EYLEA Weakness, Margin Recovery Ahead
Jul 30, 2025, 12:39 PM
Earnings Outlook
Regeneron faces near-term margin pressure from EYLEA declines, but Dupixent’s strong growth and inventory normalization could stabilize earnings by Q3 2025.